Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Nearly 1 in 10 adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to a new CDC analysis spanning eight RSV seasons. Most alarming: 467 patients died after being discharged somewhere other than hospice — meaning their deaths were likely unexpected. Researchers say the findings underscore the urgent need for RSV vaccination and stronger post-discharge follow-up care.
A new CDC analysis of over 18,000 adult RSV hospitalizations across eight seasons (2014–2024) reveals a sobering mortality picture: 8.6% of patients died either during hospitalization or within 30 days of discharge. While more than half of those deaths occurred in the hospital, a particularly concerning group — 467 patients — died after being discharged somewhere other than hospice, suggesting their deaths were unexpected.
Presented at IDWeek, the findings highlight a hidden post-discharge mortality burden that has remained remarkably consistent across seasons. CDC's Dr. Michael Melgar called this group "the most concerning," noting these patients were likely sent home or to a higher level of care without anticipation of imminent death. The data support stronger discharge planning, early post-discharge follow-up, and broader uptake of RSV vaccines, which have shown 75% effectiveness against RSV hospitalization since their 2023–2024 debut.
By the Numbers:
Why it matters: RSV has long been underestimated as a mortality risk in adults. This analysis reveals that the danger doesn't end at discharge — making vaccination, careful discharge planning, and close post-hospital follow-up critical tools for saving lives.
